Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.37 |
| ▸ | CDK8 | P49336 | 3/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 12/20 | 0.34 |
| ▸ | FNTB | P49356 | 12/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995860 | 0.91 | CCNC (0.46) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6990680 | 0.87 | KDM4E (0.50) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6990248 | 0.81 | CCNC (0.30) | CCNCCDK8CDK19 | |
| SCHEMBL6990670 | 0.77 | CCNC (0.60) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6987272 | 0.73 | MEN1 (0.57) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6991063 | 0.71 | CCNC (0.50) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6990391 | 0.64 | — | — | |
| SCHEMBL6993000 | 0.63 | FNTA (0.32) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL18429106 | 0.59 | CCNC (0.79) | CCNCCDK8CDK19KDM4EALDH1A1 | |
| SCHEMBL6986479 | 0.59 | KDM4E (0.52) | CCNCCDK8CDK19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931074-B1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6489351-B1 | POSSESSES CELL DIFFERENTIATION INDUCING FACTOR ACTION-ENHANCING ACTIVITY AND ANTI-MATRIX METALLOPROTEASE ACTIVITY AND THAT IS USEFUL IN THE PREVENTION AND TREATMENT OF BONE DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6391905-B1 | 4,5-DIHYDRO-8-METHYLTHIO-2-PHENYLFURO(3,4-E)BENZOTHIAZOLE-6-CA RBOXYLIC ACID, FOR EXAMPLE; ANTI-MATRIX METALLOPROTEASE ACTIVITY; FOR BONE DISEASES SUCH AS OSTEOPOROSIS, RHEUMATOID ARTHRITIS, CANCER METASTASIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020049242-A1 | Condensed 4,5,6,7-tetrahydrobenzo[C]thiopenes as enhancer for cell differentiation induction factor action | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6242471-B1 | BONE DISORDERS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, CANCER METASTASIS, NERVOUS SYSTEM AND BRAIN DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6066658-A | FOR PREVENTION AND TREATMENT OF BONE DISEASES SUCH AS OSTEOPOROSIS, BONE FRACTURES, OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, CANCER METASTASIS, AND DISEASES BASED ON NERVE DEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0931074-A1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | Takeda Chemical Industries, Ltd. (JP) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009958-A1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO[C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049242-A1 | Condensed 4,5,6,7-tetrahydrobenzo[C]thiopenes as enhancer for cell differentiation induction factor action | ACIN1, NFE2, NFE2L2 | CCNC 867/4885CDK8 1156/4885CDK19 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.